Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Group 1 - Altimmune, Inc. is set to report its fourth quarter 2025 financial results on March 5, 2026 [1] - A conference call will be held at 8:30 a.m. ET on the same day to discuss the financial results and provide a business update, which will be webcast live [2] - The company is focused on developing pemvidutide, a dual-action therapy for serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD) [3] Group 2 - Pemvidutide targets both glucagon and GLP-1 receptors in a balanced 1:1 ratio [3] - Altimmune is positioned as a late clinical-stage biopharmaceutical company specializing in therapies for serious liver diseases [3]